Good riddance to the term "refractory anemia" in myelodysplastic syndromes

Area of Science:

• Hematology
• Medical History
• Oncology

Background:

• The term "refractory anemia" was introduced in 1937 and later incorporated into classifications of myelodysplastic syndromes (MDS).
• Historical issues surrounding the term include its association with unethical experiments and racially offensive conduct by its originator, Cornelius Parker Rhoads.
• The term has also presented terminological challenges and diagnostic confusion in clinical practice.

Observation:

• The World Health Organization (WHO) proposed eliminating "refractory anemia" in its 2016 reclassification of myeloid neoplasia.
• The original 1937 description of "refractory anemia" may not accurately represent current understanding of myelodysplastic syndromes.
• The historical controversy and ongoing diagnostic ambiguity surrounding the term highlight its limitations.

Findings:

• The historical baggage and problematic usage of "refractory anemia" warrant its removal from medical terminology.
• The evolution of hematological classifications demonstrates a need for precise and unambiguous diagnostic terms.
• The proposed WHO reclassification addresses these issues by suggesting the elimination of "refractory anemia".

Implications:

• Eliminating "refractory anemia" will improve diagnostic clarity and reduce confusion in the classification of myeloid neoplasms.
• This change aligns with the ongoing efforts to refine and update medical terminology based on scientific advancements and ethical considerations.
• The reclassification supports more accurate research and clinical management of patients with related hematological conditions.